HIV-1 Consensus Envelope-Induced Broadly Binding Antibodies

AIDS Research and Human Retroviruses

Volumn 33, Issue 8, 2017, Pages 859-868

  Meyerhoff, R Ryan ^a,b   Scearce, Richard M ^a   Ogburn, Damon F ^a   Lockwood, Brad ^a   Pickeral, Joy ^a,b   Kuraoka, Masa ^b   Anasti, Kara ^a   Eudailey, Joshua ^a   Eaton, Amanda ^a   Cooper, Melissa ^a   Wiehe, Kevin ^a   Montefiori, David C ^a,b   Tomaras, Georgia ^a,b   Ferrari, Guido ^a,b   Alam, S Munir ^a   Liao, Hua Xin ^a,c   Korber, Bette ^d   Gao, Feng ^a   Haynes, Barton F ^a,b  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c JINAN UNIVERSITY   (China)

^d LOS ALAMOS NATIONAL LABORATORY   (United States)

Author keywords

ADCC; antibody mediated immunity; HIV; monoclonal; vaccine design

Indexed keywords

CON 6 PROTEIN; DODECYL SULFATE SODIUM; GLYCOPROTEIN GP 120; IMMUNOGLOBULIN G1 ANTIBODY; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 13D7; MONOCLONAL ANTIBODY 16H3; MONOCLONAL ANTIBODY 18F11; MONOCLONAL ANTIBODY 3B3; REAGENT; RECOMBINANT PROTEIN; RECOMBINANT VIRUS ENVELOPE PROTEIN; UNCLASSIFIED DRUG; VIRAL PROTEIN; VIRUS ENVELOPE PROTEIN; EPITOPE; HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY; HUMAN IMMUNODEFICIENCY VIRUS VACCINE;

AMINO TERMINAL SEQUENCE; ANIMAL CELL; ANIMAL EXPERIMENT; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ANTIGEN BINDING; ARTICLE; CARBOXY TERMINAL SEQUENCE; CD4+ T LYMPHOCYTE; CONSENSUS SEQUENCE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; EPITOPE MAPPING; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNOREACTIVITY; MOUSE; NONHUMAN; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; VIRUS ENVELOPE; VIRUS RECOMBINANT; WESTERN BLOTTING; ANIMAL; BAGG ALBINO MOUSE; GENETICS; IMMUNOLOGY; ISOLATION AND PURIFICATION;

AIDS VACCINES; ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODY-DEPENDENT CELL CYTOTOXICITY; CONSENSUS SEQUENCE; ENV GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; EPITOPE MAPPING; EPITOPES; HIV ANTIBODIES; HIV-1; MICE, INBRED BALB C;

EID: 85027078808     PISSN: 08892229     EISSN: 19318405     Source Type: Journal    
DOI: 10.1089/aid.2016.0294     Document Type: Article

References (58)

1. Bradley T, Fera D, Bhiman J, et al.: Structural constraints of vaccine-induced tier-2 autologous HIV neutralizing antibodies targeting the receptor-binding site. Cell Rep 2016;14: 43-54.
2. Haynes BF, Gilbert PB, McElrath MJ, et al.: Immunecorrelates analysis of an HIV-1 vaccine efficacy trial. N Engl J Med 2012;366:1275-1286.
3. Haynes BF, Kelsoe G, Harrison SC, Kepler TB: B-celllineage immunogen design in vaccine development with HIV-1 as a case study. Nat Biotechnol 2012;30:423-433.
4. Hu JK, Crampton JC, Cupo A, et al.: Murine antibody responses to cleaved soluble HIV-1 envelope trimers are highly restricted in specificity. J Virol 2015;89:10383-10398.
5. Jardine J, Julien JP, Menis S, et al.: Rational HIV immunogen design to target specific germline B cell receptors. Science 2013;340:711-716.
6. Kang YK, Andjelic S, Binley JM, et al.: Structural and immunogenicity studies of a cleaved, stabilized envelope trimer derived from subtype A HIV-1. Vaccine 2009;27: 5120-5132.
7. Rerks-Ngarm S, Pitisuttithum P, Nitayaphan S, et al.: Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N Engl J Med 2009;361:2209-2220.
8. Williams WB, Liao HX, Moody MA, et al.: HIV-1 VACCINES. Diversion of HIV-1 vaccine-induced immunity by gp41-microbiota cross-reactive antibodies. Science 2015;349: aab1253.
9. Bonsignori M, Hwang KK, Chen X, et al.: Analysis of a clonal lineage of HIV-1 envelope V2/V3 conformational epitope-specific broadly neutralizing antibodies and their inferred unmutated common ancestors. J Virol 2011;85: 9998-10009.
10. Bonsignori M, Wiehe K, Grimm SK, et al.: An autoreactive antibody from an SLE/HIV-1 individual broadly neutralizes HIV-1. J Clin Invest 2014;124:1835-1843.
11. Bonsignori M, Zhou T, Sheng Z, et al.: Maturation pathway from germline to broad HIV-1 neutralizer of a CD4-Mimic antibody. Cell 2016;165:449-463.
12. Calarese DA, Scanlan CN, Zwick MB, et al.: Antibody domain exchange is an immunological solution to carbohydrate cluster recognition. Science 2003;300:2065-2071.
13. Doria-Rose NA, Bhiman JN, Roark RS, et al.: New member of the V1V2-Directed CAP256-VRC26 lineage that shows increased breadth and exceptional potency. J Virol 2015;90:76-91.
14. Garces F, Lee JH, de Val N, et al.: Affinity maturation of a potent family of HIV antibodies is primarily focused on accommodating or avoiding glycans. Immunity 2015;43: 1053-1063.
15. Liao HX, Lynch R, Zhou T, et al.: Co-evolution of a broadly neutralizing HIV-1 antibody and founder virus. Nature 2013;496:469-476.
16. Pejchal R, Doores KJ, Walker LM, et al.: A potent and broad neutralizing antibody recognizes and penetrates the HIV glycan shield. Science 2011;334:1097-1103.
17. Scharf L, Scheid JF, Lee JH, et al.: Antibody 8ANC195 reveals a site of broad vulnerability on the HIV-1 envelope spike. Cell Rep 2014;7:785-795.
18. Sok D, van Gils MJ, Pauthner M, et al.: Recombinant HIV envelope trimer selects for quaternary-dependent antibodies targeting the trimer apex. Proc Natl Acad Sci U S A 2014; 111:17624-17629.
19. Walker LM, Huber M, Doores KJ, et al.: Broad neutralization coverage of HIV by multiple highly potent antibodies. Nature 2011;477:466-470.
20. Walker LM, Phogat SK, Chan-Hui PY, et al.: Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target. Science 2009;326:285-289.
21. Zhu J, O'Dell S, Ofek G, et al.: Somatic populations of PGT135-137 HIV-1-neutralizing antibodies identified by 454 pyrosequencing and bioinformatics. Front Microbiol 2012;3:315.
22. Zhu Z, Qin HR, Chen W, et al.: Cross-reactive HIV-1-neutralizing human monoclonal antibodies identified from a patient with 2F5-like antibodies. J Virol 2011;85:11401-11408.
23. Yang X, Lipchina I, Cocklin S, Chaiken I, Sodroski J: Antibody binding is a dominant determinant of the efficiency of human immunodeficiency virus type 1 neutralization. J Virol 2006;80:11404-11408.
24. Liu P, Williams LD, Shen X, et al.: Capacity for infectious HIV-1 virion capture differs by envelope antibody specificity. J Virol 2014;88:5165-5170.
25. Bonsignori M, Pollara J, Moody MA, et al.: Antibodydependent cellular cytotoxicity-mediating antibodies from an HIV-1 vaccine efficacy trial target multiple epitopes and preferentially use the VH1 gene family. J Virol 2012;86: 11521-11532.
26. Ferrari G, Pollara J, Kozink D, et al.: An HIV-1 gp120 envelope human monoclonal antibody that recognizes a C1 conformational epitope mediates potent antibodydependent cellular cytotoxicity (ADCC) activity and defines a common ADCC epitope in human HIV-1 serum. J Virol 2011;85:7029-7036.
27. Pollara J, Bonsignori M, Moody MA, Pazgier M, Haynes BF, Ferrari G: Epitope specificity of human immunodeficiency virus-1 antibody dependent cellular cytotoxicity [ADCC] responses. Curr HIV Res 2013;11:378-387.
28. Gao F, Scearce RM, Alam SM, et al.: Cross-reactive monoclonal antibodies to multiple HIV-1 subtype and SIVcpz envelope glycoproteins. Virology 2009;394:91-98.
29. Ma BJ, Alam SM, Go EP, et al.: Envelope deglycosylation enhances antigenicity of HIV-1 gp41 epitopes for both broad neutralizing antibodies and their unmutated ancestor antibodies. PLoS Pathog 2011;7:e1002200.
30. Palker TJ, Scearce RM, Miller SE, et al.: Monoclonal antibodies against human T cell leukemia-lymphoma virus (HTLV) p24 internal core protein. Use as diagnostic probes and cellular localization of HTLV. J Exp Med 1984;159: 1117-1131.
31. Moody MA, Yates NL, Amos JD, et al.: HIV-1 gp120 vaccine induces affinity maturation in both new and persistent antibody clonal lineages. J Virol 2012;86:7496-7507.
32. Kuraoka M, Schmidt AG, Nojima T, et al.: Complex antigens drive permissive clonal selection in germinal centers. Immunity 2016;44:542-552.
33. Rohatgi S, Ganju P, Sehgal D. Systematic design and testing of nested (RT-)PCR primers for specific amplification of mouse rearranged/expressed immunoglobulin variable region genes from small number of B cells. J Immunol Methods. Dec 31 2008;339:205-219.
34. Tiller T, Busse CE, Wardemann H. Cloning and expression of murine Ig genes from single B cells. J Immunol Methods. Oct 31 2009;350:183-193.
35. Edmonds TG, Ding H, Yuan X, et al.: Replication competent molecular clones of HIV-1 expressing Renilla luciferase facilitate the analysis of antibody inhibition in PBMC. Virology. Dec 05 2010;408:1-13.
36. Montefiori DC: Evaluating neutralizing antibodies against HIV, SIV, and SHIV in luciferase reporter gene assays. Curr Protoc Immunol 2005;Chapter 12:Unit 12.11.
37. Crooks GE, Hon G, Chandonia JM, Brenner SE. WebLogo: a sequence logo generator. Genome Res. Jun 2004;14: 1188-1190.
38. Pancera M, Majeed S, Ban YE, et al.: Structure of HIV-1 gp120 with gp41-interactive region reveals layered envelope architecture and basis of conformational mobility. Proc Natl Acad Sci U S A 2010;107:1166-1171.
39. Julien JP, Cupo A, Sok D, et al.: Crystal structure of a soluble cleaved HIV-1 envelope trimer. Science 2013;342: 1477-1483.
40. Korber B, Gaschen B, Yusim K, Thakallapally R, Kesmir C, Detours V: Evolutionary and immunological implications of contemporary HIV-1 variation. Br Med Bull 2001; 58:19-42.
41. Wei X, Decker JM, Wang S, et al.: Antibody neutralization and escape by HIV-1. Nature 2003;422:307-312.
42. Doores KJ, Burton DR: Variable loop glycan dependency of the broad and potent HIV-1-neutralizing antibodies PG9 and PG16. J Virol 2010;84:10510-10521.
43. Doria-Rose NA, Schramm CA, Gorman J, et al.: Developmental pathway for potent V1V2-directed HIV-neutralizing antibodies. Nature 2014;509:55-62.
44. Garces F, Sok D, Kong L, et al.: Structural evolution of glycan recognition by a family of potent HIV antibodies. Cell 2014;159:69-79.
45. Scanlan CN, Pantophlet R, Wormald MR, et al.: The broadly neutralizing anti-human immunodeficiency virus type 1 antibody 2G12 recognizes a cluster of alpha1 - >2 mannose residues on the outer face of gp120. J Virol 2002; 76:7306-7321.
46. Sok D, Doores KJ, Briney B, et al.: Promiscuous glycan site recognition by antibodies to the high-mannose patch of gp120 broadens neutralization of HIV. Sci Transl Med 2014;6:236ra263.
47. Behrens AJ, Vasiljevic S, Pritchard LK, et al.: Composition and antigenic effects of individual glycan sites of a trimeric HIV-1 envelope glycoprotein. Cell Rep 2016;14:2695-2706.
48. Liao HX, Chen X, Munshaw S, et al.: Initial antibodies binding to HIV-1 gp41 in acutely infected subjects are polyreactive and highly mutated. J Exp Med 2011;208: 2237-2249.
49. Haynes BF, Moody MA, Verkoczy L, Kelsoe G, Alam SM: Antibody polyspecificity and neutralization of HIV-1: A hypothesis. Hum Antibodies 2005;14:59-67.
50. Scheid JF, Mouquet H, Feldhahn N, et al.: Broad diversity of neutralizing antibodies isolated from memory B cells in HIV-infected individuals. Nature 2009;458:636-640.
51. Trama AM, Moody MA, Alam SM, et al.: HIV-1 envelope gp41 antibodies can originate from terminal ileum B cells that share cross-reactivity with commensal bacteria. Cell Host Microbe 2014;16:215-226.
52. Scanlan CN, Ritchie GE, Baruah K, et al.: Inhibition of mammalian glycan biosynthesis produces non-self antigens for a broadly neutralising, HIV-1 specific antibody. J Mol Biol 2007;372:16-22.
53. Kong L, Torrents de la Pena A, Deller MC, et al.: Complete epitopes for vaccine design derived from a crystal structure of the broadly neutralizing antibodies PGT128 and 8ANC195 in complex with an HIV-1 Env trimer. Acta Crystallogr D Biol Crystallogr 2015;71(Pt 10):2099-2108.
54. Sanders RW, van Gils MJ, Derking R, et al.: HIV-1 VACCINES. HIV-1 neutralizing antibodies induced by native-like envelope trimers. Science 2015;349:aac4223.
55. Tomaras GD, Ferrari G, Shen X, et al.: Vaccine-induced plasma IgA specific for the C1 region of the HIV-1 envelope blocks binding and effector function of IgG. Proc Natl Acad Sci U S A 2013;110:9019-9024.
56. Acharya P, Tolbert WD, Gohain N, et al.: Structural definition of an antibody-dependent cellular cytotoxicity response implicated in reduced risk for HIV-1 infection. J Virol 2014;88:12895-12906.
57. Guan Y, Pazgier M, Sajadi MM, et al.: Diverse specificity and effector function among human antibodies to HIV-1 envelope glycoprotein epitopes exposed by CD4 binding. Proc Natl Acad Sci U S A 2013;110:E69-E78.
58. Moore JP, McCutchan FE, Poon SW, et al.: Exploration of antigenic variation in gp120 from clades A through F of human immunodeficiency virus type 1 by using monoclonal antibodies. J Virol 1994;68:8350-8364.